In a striking advancement for cancer research, Rice University has secured new funding from the Cancer Prevention and Research Institute of Texas (CPRIT) aimed at deepening scientific inquiry and innovation in oncology. This multi-faceted investment promises not only to bolster the infrastructure that supports cutting-edge genetic engineering but also to propel forward several high-impact research projects in cancer immunotherapy and ovarian cancer. The initiative is further poised to attract top-tier researchers, potentially reshaping the landscape of cancer treatment research in Texas and beyond.
The centerpiece of this funding surge is the substantial renewal and expansion of Rice’s Genetic Design and Engineering Center (GDEC). Established initially in 2022 with support from CPRIT, GDEC functions as a pivotal biotech core facility dedicated to the development and provision of intricate DNA tools for cancer and biomedical researchers. The infusion of $2 million will facilitate the addition of an automated mammalian cell hub, vastly enhancing GDEC’s capabilities to generate sophisticated cell models and conduct high-throughput, precise manipulation of mammalian cells. This expansion integrates synthetic biology and genome engineering with robotic automation, streamlining complex processes that previously demanded extensive manual effort.
At the core of GDEC’s mission lies the ability to bridge synthetic biology with genome editing technologies, enabling researchers to design novel genetic circuits and engineer specific genomic alterations with high precision. Leveraging CRISPR-based technologies and next-generation DNA synthesis, the center accelerates exploratory cancer biology studies by creating customized cellular models that mimic tumor biology and treatment responses. The automated mammalian cell hub represents a transformative leap, empowering large-scale production and manipulation of these models under tightly controlled conditions, indispensable for in vitro and preclinical testing.
This technological advancement arrives at a crucial juncture when cancer treatment paradigms are rapidly evolving. The five-year relative survival rate for all cancers in the U.S. has climbed to 70%, a notable increase from the less optimistic rates in the 1970s. Breakthroughs in targeted therapies and immunotherapies have catalyzed this progress, focusing scientific efforts on treatments that exploit the biological intricacies of tumors and the immune microenvironment. Immunotherapy, particularly through engineered T cell variants, is among the most promising strategies intensively explored at Rice, where mechanistic insights are coupled with engineering tactics to refine therapeutic efficacy.
Within this broader landscape, three key projects—spearheaded by eminent Rice faculty—are channeling CPRIT support to tackle critical challenges in cancer treatment through innovative biological insights. Assistant Professor Anna-Karin Gustavsson’s work on live visualization techniques aims to decode dynamic biological responses to radiation therapy, leveraging sophisticated imaging and biosensors to inform and optimize next-generation therapeutic protocols. This approach not only refines radiation precision but also uncovers cellular pathways that confer resistance or sensitivity, illuminating pathways for combinatorial interventions.
Professor Peter Lillehoj, an expert in mechanical engineering, approaches cancer immunotherapy from a bioengineering perspective, focusing on the enhancement of cancer-fighting T cells. His research integrates microscale engineering and immunological profiling, striving to optimize T cell activation, persistence, and tumor infiltration. The engineering of these lymphocytes demands precise control over cellular biomechanics and signaling pathways, a frontier where mechanical forces intersect with immunomodulation. This initiative stands to expand the therapeutic repertoire of cell-based immunotherapies, particularly in aggressive hematological malignancies.
In parallel, Professor Cynthia Reinhart-King investigates how aging influences ovarian cancer progression. This examination of the tumor microenvironment within aged tissues sheds light on the altered biophysical and biochemical cues that potentiate cancer spread in elderly populations. Her research transcends traditional molecular biology by embedding principles of tissue mechanics and cellular microenvironmental changes, unveiling age-dependent vulnerabilities that could be exploited for targeted interventions. This holistic perspective is crucial for developing therapies tailored to the complex realities of cancer in aged patients.
Central to these endeavors is the synergy created between innovative core facilities and expert-led research. Gang Bao, Foyt Family Professor of Bioengineering, along with colleagues Caleb Bashor and Elizabeth Gardner, steward the GDEC’s expansive capabilities to provide essential genetic engineering resources. Their leadership ensures the seamless integration of synthetic biology with high-throughput automation, enabling groundbreaking projects in cancer genetics and immunoengineering to proceed at an unprecedented scale and speed. The facility’s robotic platforms execute intricate genome editing, DNA assembly, and cell culture with precision and reproducibility rarely attainable in traditional laboratory environments.
This orchestration of expertise and technology underscores a broader trend in oncology research: the convergence of engineering, synthetic biology, and immunology to develop precise, patient-tailored therapies. The CPRIT-funded expansion at Rice exemplifies how state-of-the-art infrastructure can catalyze collaborative science, accelerate discovery, and ultimately translate into clinical breakthroughs. By automating labor-intensive processes and fostering interdisciplinary research, the GDEC aims to empower the scientific community to overcome complex biological challenges and pioneer novel cancer treatments.
Moreover, the robust institutional support signals a commitment to academic excellence and scientific leadership in Texas, aiming to attract distinguished researchers whose work will enhance cancer research programs significantly. This strategy includes recruiting faculty with diverse expertise capable of bridging fundamental research and translational medicine. The potential expansion of Rice’s research faculty through CPRIT funding is anticipated to spur innovation clusters around cancer biology, cell engineering, and therapeutic development.
The increasing efficacy of cancer treatments owes much to the transition from nonspecific cytotoxic approaches toward therapies designed with molecular and cellular precision. By embracing this evolution, Rice University and CPRIT are affirming their roles as pivotal contributors in the pursuit to understand cancer’s complexity and devise transformative medical interventions. The augmented GDEC facility and supported projects are poised to dissect cancer mechanisms with unprecedented clarity, engineering solutions from cellular constituents upward.
Initiatives like these underscore the essential role of centralized core facilities that couple advanced technology platforms with expert knowledge. Such centers not only democratize access to cutting-edge tools but also enhance reproducibility and throughput in experimental workflows. The GDEC’s continued growth exemplifies this model, which stands as a beacon for collaborative research ecosystems, fostering innovation that can be swiftly translated into clinical contexts.
In essence, the recent CPRIT funding marks a strategic investment in the technological and intellectual infrastructure necessary for next-generation cancer research. Through a coordinated emphasis on genetic engineering, immunotherapy enhancement, and age-related cancer biology, Rice University is positioning itself at the forefront of efforts to transform cancer treatment paradigms. The coming years hold promise for breakthroughs that could redefine patient outcomes and establish new standards in oncological care.
Subject of Research: Cancer research, genetic engineering, immunotherapy, radiation therapy, ovarian cancer, aging and cancer progression
Article Title: Not provided
News Publication Date: June 8, 2026
Web References:
– https://profiles.rice.edu/faculty/anna-karin-gustavsson
– https://profiles.rice.edu/faculty/peter-b-lillehoj
– https://profiles.rice.edu/faculty/cynthia-reinhart-king
– https://profiles.rice.edu/faculty/gang-bao
– https://profiles.rice.edu/faculty/caleb-bashor
– https://profiles.rice.edu/faculty/elizabeth-gardner
Image Credits: Photo by Jeff Fitlow/Rice University
Keywords: Cancer treatments, Cancer immunology, Ovarian cancer, Immunotherapy, Medical treatments, Radiation therapy, Cell therapies, Scientific community, Scientific facilities
Tags: automated mammalian cell hubbiomedical research infrastructure developmentcancer immunotherapy researchCPRIT cancer research fundingGenetic Design and Engineering Center expansiongenome engineering advancementshigh-throughput cell model generationovarian cancer studiesRice University cancer researchrobotic automation in geneticssynthetic biology in oncologyTexas cancer treatment innovation
